Exploring 3 High Growth Tech Stocks In Sweden
In This Article:
Sweden's tech market has shown resilience and potential for high growth, particularly as global markets rebound from recent sell-offs and the European Central Bank cuts rates to stimulate economic activity. In this context, identifying promising tech stocks involves looking at companies that not only innovate but also adapt well to shifting market dynamics and economic indicators.
Top 10 High Growth Tech Companies In Sweden
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Truecaller | 20.32% | 21.61% | ★★★★★★ |
| Fortnox | 20.18% | 22.60% | ★★★★★★ |
| Xbrane Biopharma | 53.90% | 118.02% | ★★★★★★ |
| Yubico | 20.52% | 42.35% | ★★★★★★ |
| Bonesupport Holding | 33.76% | 31.20% | ★★★★★★ |
| Scandion Oncology | 40.71% | 75.34% | ★★★★★★ |
| Hemnet Group | 20.13% | 25.41% | ★★★★★★ |
| Skolon | 31.76% | 121.72% | ★★★★★★ |
| BioArctic | 42.38% | 98.40% | ★★★★★★ |
| KebNi | 34.75% | 86.11% | ★★★★★★ |
We're going to check out a few of the best picks from our screener tool.
Fortnox
Simply Wall St Growth Rating: ★★★★★★
Overview: Fortnox AB (publ) offers a range of financial and administrative products, packages, and integrations tailored for small and medium-sized businesses, accounting firms, and organizations with a market cap of SEK38.49 billion.
Operations: The company generates revenue primarily from core products (SEK734 million), businesses (SEK378 million), accounting firms (SEK352 million), financial services (SEK249 million), and marketplaces (SEK160 million). The market cap stands at SEK38.49 billion.
Fortnox's revenue is forecast to grow at 20.2% annually, significantly outpacing the Swedish market's 1% growth rate. The company's earnings are expected to increase by 22.6% per year, reflecting robust performance compared to the market's 15.2%. In the past year, Fortnox saw its earnings surge by 48.1%, surpassing the software industry's average of 14.5%. Recent reports show a strong second quarter with SEK 521 million in revenue and SEK 164 million in net income, highlighting its solid financial footing and promising future prospects in SaaS models ensuring recurring revenue from subscriptions.
-
Click here and access our complete health analysis report to understand the dynamics of Fortnox.
-
Gain insights into Fortnox's historical performance by reviewing our past performance report.
Swedish Orphan Biovitrum
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Swedish Orphan Biovitrum AB (publ) is an integrated biotechnology company that researches, develops, manufactures, and sells pharmaceuticals in haematology, immunology, and specialty care across Europe, North America, the Middle East, Asia, and Australia with a market cap of SEK113.92 billion.